DNMT inhibitors, such as azacytidine and decitabine (DAC), are FDA-approved for treating hematological conditions like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [62]. Here, DNMT1 is linked to myelodysplastic syndrome.